Individuals diagnosed with Parkinson’s disease exhibit a diminished capacity to appreciate pleasant olfactory stimuli, such as the scent of lemon. This observation has led researchers to the conclusion that the condition alters how afflicted individuals perceive smells, suggesting that an altered sense of smell could potentially serve as a means for doctors to diagnose Parkinson’s disease. Such a diagnostic method could be both cost-effective and non-invasive, significantly streamlining a process that currently often spans several years and involves numerous assessments.
A decline in the sense of smell is a cardinal symptom of Parkinson’s disease, impacting between 75% and 90% of patients. This olfactory deficit frequently emerges years, or even decades, before the motor symptoms, like tremors, become apparent. While numerous attempts have been made to leverage this loss of smell as a diagnostic indicator, these efforts have been complicated by the natural decline in olfactory function that accompanies healthy aging. This presents a challenge in distinguishing disease-specific changes from age-related ones.
In response to this challenge, a team led by Noam Sobel at the Weizmann Institute of Science in Rehovot, Israel, explored a novel approach focusing on the nuanced perception of smells rather than just their detection. For their study, the researchers enlisted 94 participants, predominantly in their late 50s to late 60s. This group was divided into three categories: 33 individuals with a confirmed Parkinson’s disease diagnosis, 33 participants with no known medical conditions, and 28 individuals demonstrating smell dysfunction unrelated to Parkinson’s disease.
The researchers employed a combination of established diagnostic methods and their own innovative techniques to assess participants’ olfactory capabilities. Standardized tests and questionnaires were used to gauge the ability to detect and identify various odors. Additionally, the team developed specialized tests designed to capture what they term an “olfactory perceptual fingerprint.” These bespoke assessments required participants to rate the intensity and pleasantness of scents originating from three distinct containers.
One container held a high concentration of citral, an odorant that imparts a lemon-like aroma. A second container contained a potent mixture of asafoetida and skatole, ingredients known for their strong, sometimes faecal, odor when concentrated. The third container was left empty. These specific olfactory challenges allowed for a more detailed analysis of how individuals processed and responded to different types of smells.
While all the conducted tests successfully identified participants experiencing a general decline in their ability to sense smells, only the “olfactory perceptual fingerprints” demonstrated the capacity to differentiate between individuals with smell loss who did or did not have Parkinson’s disease. This novel approach achieved an 88% accuracy rate in distinguishing between these groups. The accuracy further improved to 94% when factors such as the participants’ age and sex were standardized to match across groups.
The study’s findings revealed that individuals with Parkinson’s disease rated the intensity of the citrus smell comparably to the healthy control group, and even more intensely than those with smell issues unrelated to the disease. However, when the pleasantness of the lemon scent was evaluated, both groups experiencing olfactory dysfunction reported lower scores than the healthy participants. Intriguingly, individuals with Parkinson’s prolonged their sniffing duration by nearly 2% in response to the unpleasant, faecal-like smell compared to the lemon scent. Conversely, participants in the other groups shortened their sniffing duration by a significant 11% to 12% in reaction to the unpleasant odor.
Sobel and his colleagues hypothesize that while the physical mechanisms of smelling within the nose may function adequately in individuals with Parkinson’s, the brain processes these olfactory signals differently. This altered brain processing, they suggest, leads to a reduced perception of pleasure from agreeable odors and a sniffing response that appears decoupled from the inherent pleasantness of a scent.
This distinct olfactory processing in Parkinson’s disease may be linked to changes in specific brain regions. The anterior olfactory nucleus, for instance, is known to shrink when deprived of olfactory signals and is suspected to be among the earliest sites affected by the neuropathology of Parkinson’s disease. The current research provides further indirect support for the involvement of central olfactory processing pathways in the condition.
Differentiating between age-related smell loss and olfactory deficits specifically linked to Parkinson’s disease holds significant clinical value, according to Michał Pieniak at the Smell & Taste Clinic at the Dresden University of Technology in Germany. He notes that approximately one in ten patients presenting with unexplained smell loss will eventually develop Parkinson’s disease. Therefore, any method that could help estimate an individual’s personal risk would be highly beneficial for early identification and management.
Charles Greer, a researcher at Yale School of Medicine, views the approach as promising, though he emphasizes the need for validation through studies involving larger patient cohorts. He also suggests that establishing the long-term reliability of such tests might require considerable time, given that olfactory loss can manifest many years before other characteristic symptoms of Parkinson’s disease become apparent.